European Commission Approves BMS’ New Plaque Psoriasis Drug

Bristol Meyer Squib (BMS) has scored a win with the European Commission (EC) approval of Sotyktu, its new treatment for plaque psoriasis. The treatment would be the first of its kind, an oral allosteric tyrosine kinase inhibitor. The approval covers adults with moderate-to-severe psoriasis that may benefit from systemic treatment for the disease.

According to Emily Kimber, “The EC’s decision was supported by positive results from the phase 3 POETYK PSO-1 and POETYK PSO-2 trials, which evaluated once-daily Sotyktu in patients with moderate-to-severe plaque psoriasis versus placebo and twice-daily Otezla (apremilast), as well as an additional two years of data from the POETYK PSO long-term extension trial.”

To read more, click here.

(Source: PM Live, March 31^st, 2023)